Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 13/20 | 0.74 |
| ▸ | MEN1 | O00255 | 3/20 | 0.67 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.67 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.66 |
| ▸ | NPC1 | O15118 | 1/20 | 0.65 |
| ▸ | RAB9A | P51151 | 1/20 | 0.65 |
| ▸ | FPR2 | P25090 | 1/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.56 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14072843 | 0.87 | EPHX2 (0.74) | EPHX2MEN1KMT2AEPHX1NPC1 | |
| SCHEMBL13768765 | 0.87 | EPHX2 (0.72) | EPHX2EPHX1RAB9A | |
| SCHEMBL1425023 | 0.86 | EPHX2 (0.74) | EPHX2MEN1KMT2AEPHX1NPC1 | |
| SCHEMBL24381938 | 0.86 | MEN1 (0.74) | EPHX2MEN1KMT2AEPHX1NPC1 | |
| SCHEMBL4997641 | 0.86 | EPHX2 (0.73) | EPHX2KMT2AEPHX1RAB9AALDH1A1 | |
| SCHEMBL3960562 | 0.85 | EPHX2 (0.74) | EPHX2MEN1KMT2AEPHX1NPC1 | |
| SCHEMBL2717848 | 0.85 | EPHX2 (1.00) | EPHX2MEN1KMT2A | |
| SCHEMBL4010386 | 0.85 | EPHX2 (0.75) | EPHX2EPHX1NPC1RAB9AALDH1A1 | |
| SCHEMBL13657550 | 0.84 | EPHX2 (0.67) | EPHX2MEN1KMT2AEPHX1NPC1 | |
| SCHEMBL14984060 | 0.84 | EPHX2 (0.76) | EPHX2MEN1KMT2AEPHX1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101535259-A | Phenylurea compounds as soluble epoxide hydrolase inhibitors | ARETE THERAPEUTICS INC (US) | 2009-09-16 | — | — | CN | claimed |
| US-20080221100-A1 | SOLUBLE EPOXIDE HYDROLASE INHIBITORS | ARETE THERAPEUTICS, INC. | 2008-09-11 | — | — | US | claimed |
| US-20080221100-A1 | SOLUBLE EPOXIDE HYDROLASE INHIBITORS | ARETE THERAPEUTICS, INC. | 2008-09-11 | — | — | US | disclosed |
| US-20080221100-A1 | SOLUBLE EPOXIDE HYDROLASE INHIBITORS | ARETE THERAPEUTICS, INC. | 2008-09-11 | — | — | US | disclosed |
| US-20080221100-A1 | SOLUBLE EPOXIDE HYDROLASE INHIBITORS | ARETE THERAPEUTICS, INC. | 2008-09-11 | — | — | US | disclosed |
| WO-2008051873-A2 | PHENYLUREA COMPOUNDS AS SOLUBLE EPOXIDE HYDROLASE INHIBITORS | ARETE THERAPEUTICS, INC. (US) | 2008-05-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080221100-A1 | SOLUBLE EPOXIDE HYDROLASE INHIBITORS | EPHX1, EPHX2, NCEH1 | EPHX2 2/4885MEN1 3797/4885KMT2A 3884/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.